

# Human FLT1 D7 Recombinant Protein



RPPB2530

## Product Information Protein Information

### Product SKU:

RPPB2530

### Accession:

P17948

### Host:

Insect Cells.

### Protein description:

Soluble FLT1 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is disulfide-linked homodimeric, glycosylated, polypeptide containing 751 amino acids and having a molecular mass of 130 kDa. The soluble receptor protein contains only the first 7 extracellular domains (Met1-Thr751), which contain all the information necessary for high affinity ligand binding. The FLT1 fc/Chimera is purified by proprietary chromatographic techniques.

### Appearance:

Sterile Filtered White lyophilized (freeze-dried) powder.

### Synonyms:

FLT-1, FLT1, Tyrosine-protein kinase receptor FLT, Flt-1, Tyrosine-protein kinase FRT, Fms-like tyrosine kinase 1, VEGFR-1.

### Formulation:

FLT1 D1-7 was lyophilized from a concentrated (1 mg/ml) sterile solution containing PBS Buffer, pH 7.4.

### Purity:

Greater than 95.0% as determined by SDS-PAGE.

### Solubility:

It is recommended to reconstitute the lyophilized FLT1 Fc/Chimera in PBS not less than 50µg/ml, which can then be further diluted to other aqueous solutions.

### Stability:

Lyophilized FLT-1 although stable at room temperature for 3 weeks, should be stored desiccated below -18C. Upon reconstitution FLT1 should be stored at 4C between 2-7 days and for future use below -18C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles.

### Amino Acid Sequence:

MVSYWDTGVL LCALLSCLLL TGSSSGSKLK DPESLKGQTQ HIMQAGQTLH LQCRGEEAAHK WSLPEMVSKE  
SERLSITKSA CGRNGKQFCS TLTNLAQAN HTGFYSCKYL AVPTSKKKT ESAYIFISD TGRPFVEMYS  
EPEIHMTE GRELVIPCRV TSPNITVTLK KFPLDTLIPD GKRIIWDSSRK GFIISNATYK EIGLLTCEAT VNGHLYKNTY  
LTHRQNTII DVQISTPRPV KLLRGHTLV L NCTATTPLNT RVQMTWSYYPD EKNKRASVRR RIDQSNESHAN  
IFYSVLTIDK MQNKDKGLYT CRVRSGPSFK SVNTSVHIYD KAFITVKHRK QQVLETVAGK RSYRLSMKVK  
AFPSPVWVWL KDGLPATEKS ARYLTRGYSL IIKDVTEEDA GNYTILLSIK QSNVFNKTLTA TLIVNVKPKI  
YEKAVSSFPD PALYPLGSRQ ILTCTAYGIP QPTIKWFWHP CNHNHSEARC DFCSNNEESF ILDADSNMGN  
RIESITQRMA IIEGKNKMAS TLVVADSRIS GIYICIASNK VGTVGRNISF YITDVPNGFH VNLEKMPTEG  
EDLKLSTVN KFLYRDVTWI LLRTVNNRTM HYSISKQKMA ITKEHSITLN LTIMNVSLQD SGTYACRARN  
VYTGEEILQK KEITIRDQEA PYLLRNLS DH TVAISSTTL DCHANGVPEP QITWFKNNHK IQQEPGILG  
PGSSTLFIER VTEDEGVYH CKATNQKGSV ESSAYLTVQG TAASDKHTHC PPCAPELLG GPSVFLFPPK

PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG  
KEYKCKVSNK ALPAPIEKTI S.

**Biological Activity:**

The activity of FLT1/Fc was determined by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells. The ED50 for this effect is typically 10-30 ng/ml, corresponding to a specific activity of 33,333.33-100,000 units/mg.